Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

West Pharmaceutical Services

The pharmaceutical delivery components company reported fourth-quarter earnings in February of $18.9 million, or 56 cents a share, up from year-earlier earnings of $5.9 million, or 18 cents.

"Management indicated 2012 guidance reflects $0.08-0.15 earnings per share impact from Crystal Zenith products and other proprietary safety/administration devices," Jefferies analysts wrote in a Feb. 23 report. "However, WST acknowledged these sales depend on non- and pre-commercial customer use, which carries a higher risk that revenue may be lower than expected."

Forward Annual Dividend Yield: 1.8%

Rated "B+ (Buy)" by TheStreet Ratings: The company's fourth-quarter gross profit margin was about the same as it was the previous year.

West Pharmaceutical Services has weak liquidity. Its Quick Ratio is 0.98, which demonstrates a lack of ability to meet its short-term cash needs.

In the fourth quarter, stockholders' net worth increased 4.66% from the prior year.

TheStreet Ratings' price target is $47.64.

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to: tips@thestreet.com.

>To follow the writer on Twitter, go to Alexandra Zendrian.

If you liked this article you might like

Hit the 'Mother Lode' With Vale ADRs